论文部分内容阅读
目的:观察不稳定型心绞痛(UAP)患者血清C-反应蛋白(CRP)含量、可溶性细胞间黏附分子-1(sICAM-1)和血管细胞黏附分子-1(sVCAM-1)水平变化及通心络胶囊对其影响。方法:60例患者随机分为2组。常规治疗组30例采用常规西药治疗,通心络组30例在常规西药治疗基础上加用通心络胶囊。观察治疗2月。结果:UAP患者血清CRp、sICAM-1和sVCAM-1测定值均高于健康人组和稳定型心绞痛(SAP)组(P<0.05),而SAP组患者各指标均高于健康人组(P<0.05)治疗2月后2组患者血清CRP、sICAM-1和sVCAM-1测定值分别低于治疗前水平(P<0.05),2组治疗后比较,差异有显著性意义(P<0.05)。结论:通心络胶囊能明显降低不稳定型心绞痛患者血清CRP、sICAM-1和sVCAM-1含量,具有抑制动脉血管壁炎症、保护血管内皮细胞的作用。
Objective: To investigate the changes of serum C-reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial cell adhesion molecule-1 (sVCAM-1) in patients with unstable angina pectoris (UAP) Network of its impact on the capsule. Methods: Sixty patients were randomly divided into two groups. 30 cases of conventional treatment group treated with conventional western medicine, Tongxinluo group of 30 cases on the basis of conventional Western medicine plus Tongxinluo capsule. Observation and treatment in February. Results: The serum levels of CRP, sICAM-1 and sVCAM-1 in UAP patients were significantly higher than those in healthy people and SAP patients (P <0.05), while those in SAP patients were significantly higher than those in healthy people <0.05). After 2 months of treatment, the serum levels of CRP, sICAM-1 and sVCAM-1 in the two groups were lower than those before treatment (P <0.05), and the difference was significant (P <0.05) . Conclusion: Tongxinluo capsule can significantly reduce the serum levels of CRP, sICAM-1 and sVCAM-1 in patients with unstable angina pectoris, and can inhibit the inflammation of arterial wall and protect the vascular endothelial cells.